2063 related articles for article (PubMed ID: 9207752)
1. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
2. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
4. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
5. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
6. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
Katoch K; Natarajan M; Bagga A; Katoch VM
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
[TBL] [Abstract][Full Text] [Related]
8. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
10. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
[TBL] [Abstract][Full Text] [Related]
11. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
Kumar A; Girdhar A; Girdhar BK
Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
[TBL] [Abstract][Full Text] [Related]
12. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
[TBL] [Abstract][Full Text] [Related]
13. Short-term multidrug therapy in multibacillary leprosy--review of 80 cases in two provinces of China (1983-1988).
Li HY; Yu XL; Zhang MS; Duan CX; Huang WB; Zhang SB; Zhu K; Ma JF
Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):622-7. PubMed ID: 2778368
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
15. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
16. Combined regimens of one year duration in the treatment of multibacillary leprosy--II. Combined regimens with rifampicin administered during 6 months.
Pattyn SR; Groenen G; Janssens L; Deverchin J; Ghys P
Lepr Rev; 1989 Jun; 60(2):118-23. PubMed ID: 2671560
[TBL] [Abstract][Full Text] [Related]
17. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
18. Reactional states in multibacillary Hansen disease patients during multidrug therapy.
Nery JA; Vieira LM; de Matos HJ; Gallo ME; Sarno EN
Rev Inst Med Trop Sao Paulo; 1998; 40(6):363-70. PubMed ID: 10436656
[TBL] [Abstract][Full Text] [Related]
19. Serious side effects of rifampin on the course of WHO/MDT: a case report.
Namisato M; Ogawa H
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):277-82. PubMed ID: 11221090
[TBL] [Abstract][Full Text] [Related]
20. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]